Drug Profile

Olpasiran - Amgen

Alternative Names: AMG-890; ARC LPA; ARO LPA; RNAi ARC-LPA

Latest Information Update: 31 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Arrowhead Pharmaceuticals
Developer Amgen
Class Cardiovascular therapies; Small interfering RNA
Mechanism of Action Lipoprotein A expression inhibitors; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Cardiovascular disorders

Most Recent Events

11 Dec 2024 Amgen completes a phase I trial (In volunteers) in United Kingdom (SC) (NCT06411860)
10 Oct 2024 Amgen initiates a phase I trial in Healthy adult volunteers in United Kingdom (SC) (NCT06411860)
17 May 2024 Amgen plans a phase I trial in Healthy volunteers in August 2024 (SC) (NCT06411860)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com